Crescent Biopharma, a biotechnology company specialising in the development of cancer therapies, has successfully completed a public offering of shares. The company raised $125 million, pricing its shares at $14.50 per share. The shares are listed on the NASDAQ stock exchange, but they are also available for trading in the UK through various brokerages.
The public offering is a significant milestone for Crescent Biopharma, which plans to use the funds to accelerate the development of its cancer treatments. The company has several ongoing clinical trials for its lead product candidate, and the funds will help to support the expansion of its research and development efforts.
Crescent Biopharma's shares are listed on the NASDAQ stock exchange under the ticker symbol 'CRES'. The shares are also available for trading in the UK through various brokerages, including Hargreaves Lansdown and Interactive Investor.
Investors in Crescent Biopharma should be aware of their rights and obligations under UK law. As a publicly traded company, Crescent Biopharma is required to disclose certain information to its shareholders, including its financial performance and any material events that may affect the company's shares.
For UK individual investors, it is essential to do your own research and consult with a financial advisor before investing in Crescent Biopharma or any other company. You should also be aware of your rights under UK law, including the right to request information from the company and to seek compensation if you have been misled or not provided with accurate information.